Výsledky vyhledávání - "Abderrahim Fandi"

Abstract 1069: OBT076, a clinical-stage ADC, displays synergy with oxaliplatin and cisplatin in preclinical gastric cancer models

Autor: Arnima Bisht, Murray Cox, Chander Sekhar Peddaboina, Michael Crocamo, Abderrahim Fandi, Christian Rohlff

Publikováno v: Cancer Research. 82:1069-1069

CD205 is a transmembrane glycoprotein, robustly expressed in malignancies from varied histotypes, making it an ideal target for Antibody Drug Conjugate (ADC) therapy. OBT076 is a novel and selective clinical stage ADC with potent activity against CD2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86da339256d2926c002a15a3fec4f63d
https://doi.org/10.1158/1538-7445.am2022-1069

Zobrazit plný text záznamu

Phase 1 study of OBT076, a first-in-class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy, and PK/PD results

Autor: Olivier Rixe, Shou-Ching Tang, Solmaz Sahebjam, Monica M. Mita, Alain C. Mita, Lee S. Rosen, Arnima Bisht, Abderrahim Fandi, Christian Rohlff, Rutika Mehta

Publikováno v: Journal of Clinical Oncology. 40:3028-3028

3028 Background: OBT076, an Antibody Drug Conjugate (ADC) consisting of a fully human IgG1 antibody conjugated via a cleavable linker to the derivative microtubule inhibitor DM4. It has specificity for the CD205/Ly75 target antigen which is an endocy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0ed189f7947b1a212edbbf9f0e742d0
https://doi.org/10.1200/jco.2022.40.16_suppl.3028

Zobrazit plný text záznamu

Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis

Autor: Abderrahim Fandi, Caitlyn T. Solem, Ming-Hui Tai, Sandra Margunato-Debay, Marc F. Botteman, Scott Whiting, Javier Cortes, Yin Wan, Amy Ko, Jose Perez-Garcia

Publikováno v: Clinical Breast Cancer. 18:e919-e926

Background In this analysis we compared quality-adjusted survival outcomes between nab-paclitaxel (nab-P) and standard paclitaxel (Pac) using data from the nab-P phase III registration trial in metastatic breast cancer. Patients and Methods Quality-a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0610ced24a3ddb7265ef220091911669
https://doi.org/10.1016/j.clbc.2018.03.014

Zobrazit plný text záznamu

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer

Autor: Paweł Wiechno, Abderrahim Fandi, Kejian Liu, John M. Burke, Thomas E. Hutson, John D. Hainsworth, Joaquim Bellmunt, Ulf Jungnelius, Ronald de Wit, Nicholas J. Vogelzang, Edward J. Crane, Anita Gandhi, William R. Berry, Michelle Waldman, Debora Barton, Cora N. Sternberg, Karim Fizazi, Daniel P. Petrylak, Kevin Doner

Publikováno v: European Urology, 71(2), 168-171. Elsevier

Elevated circulating tumor cell (CTC) blood levels (≥5 cells/7.5ml) convey a negative prognosis in metastatic castration-resistant prostate cancer but their prognostic significance in patients receiving chemotherapy is uncertain. The association be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad5e4b782cef69c1791a9eada8dfbc0a
https://doi.org/10.1016/j.eururo.2016.07.051

Zobrazit plný text záznamu

Abstract 5167: Identification and validation of a novel immuno-oncology target and selection of a therapeutic antibody candidate with a pharmacologically beneficial activity profile

Autor: James Edward Ackroyd, Chander Peddaboina, Eugene Zhukovsky, Arnima Bisht, Lindsey Hudson, San Lin Lou, Robert Boyd, Abderrahim Fandi, Livija Deban, Martin Barnes, Angelo Kaplan, Christian Rohlff, Murray Cox, Jason D. Allen, Nickolas Attanasio

Publikováno v: Cancer Research. 80:5167-5167

Identification of novel targets in cancer immunotherapy is needed to address the significant number of patients that either do not respond to current therapies or encounter unacceptable toxicities. The first two generations of immuno-oncology drugs h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03fc1f23dc77738087c1819a3579e96d
https://doi.org/10.1158/1538-7445.am2020-5167

Zobrazit plný text záznamu

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

Autor: Ruta Slepetis, Kyle J. MacBeth, Alberto Risueño, Bilal Piperdi, Xiaoling Wu, Giuseppe Giaccone, Abderrahim Fandi, Benjamin Levy, Benjamin Besse, Enriqueta Felip, Luis Paz-Ares, Manuel Dómine Gomez, Marina Chiara Garassino, Santiago Ponce-Aix, Daniel Menezes, Pilar Garrido

Publikováno v: European journal of cancer (Oxford, England : 1990). 108

Introduction Preclinical and early clinical studies suggest that combining epigenetic agents with checkpoint inhibitors can potentially improve outcomes in patients with previously treated advanced non-small cell lung cancer (NSCLC). This phase 2 tri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f5d9346df98a718a80206039c02aeb9
https://pubmed.ncbi.nlm.nih.gov/31082689

Zobrazit plný text záznamu

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

Publikováno v: Lancet Oncology
Lancet Oncology, Elsevier, 2015, 16 (4), pp.417-425. ⟨10.1016/S1470-2045(15)70025-2⟩
Lancet Oncology, 16(4), 417-425. Lancet Publishing Group

Summary Background Patients with metastatic castration-resistant prostate cancer have few treatment options. We investigated the safety and efficacy of lenalidomide, an immunomodulatory agent with anti-angiogenic properties, in combination with docet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15480ad069a7e176c960fc4864a73a1b
https://hdl.handle.net/1765/81251

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání